Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation Welcomes Two New Board Members

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

“Peter and Joshua bring valuable business and philanthropic experience that will further advance the Parkinson’s Foundation’s mission to serve the one million Americans and ten million people worldwide living with this disease,” said John W. Kozyak, Esq., Chairman of the Board of the Parkinson’s Foundation.

Peter Goldman

Goldman is managing partner of Lakeshore Sport & Fitness in Chicago, which owns and operates businesses in the Chicago area focused on hospitality, health and wellness. Before becoming an entrepreneur, Goldman worked for Sam Zell in real estate investing and McKinsey & Company as a management consultant. He has served on several non-profit boards including the Auxiliary Board of the Art Institute of Chicago, where he was a vice president and created a new annual signature fundraising event. 

“I am excited to join the Parkinson’s Foundation board at this critical time,” Goldman said. “The Parkinson’s Foundation’s mission to make life better for people with Parkinson’s is more urgent than ever with 60,000 new cases being diagnosed every year.”

Joshua Raskin

For the past 18 years, Raskin has served as managing director at Barclay's Capital, where he coordinates coverage of the healthcare services sector in the equity research department. Prior to this, he was a managing director at Lehman Brothers for nine years. In 2017, Raskin formed Nephron Research, an independent research boutique focused on healthcare. He has a personal connection to Parkinson’s in his immediate family.

“The fight against Parkinson’s disease and the mission of finding a cure are of deep importance to me, particularly in light of my family history,” Raskin said. “I remain committed to the Parkinson’s community in my new role on the Parkinson’s Foundation board of directors.”

A complete list of the Parkinson’s Foundation’s Board of Directors is available at

About the Parkinson’s Foundation

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community. For more information, visit or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease

Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Tuesday, October 24, 2017
Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Parkinson’s Foundation Announces $1.2 Million Investment to Advance Careers, Support Innovation of Early Career Parkinson’s Scientists
Tuesday, August 8, 2017

NEW YORK & MIAMI The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.


mail icon

Subscribe to get the latest news on treatments, research and other updates.